MeiraGTx Holdings PLC at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript
Welcome, everyone. My name is Gena Wang. I'm SMID cap biotech analyst at Barclays. It's my great pleasure to introduce our next presenting company MeiraGTx. With me on the Zoom meeting is Zandy Forbes, President and Chief Executive Officer; and also Elizabeth Anderson, VP of Investor Relations.
With that, I hand over to you, Zandy.
Thank you, Gena, and thank you for Barclays inviting us to speak and chat with you at this conference. I'm going to give a quick overview of the company. And then I think we will touch on a number of aspects I'm going to mention in our conversation. So if we could go to the first slide, please, Elizabeth.
So Meira is a gene therapy company that was really formed to address or innovate in this new space of gene therapy to create pharmaceuticals that could cost effectively treat a broad range of serious disorders. That means that from the perspective of Meira, we're really
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
